(19)
(11) EP 4 581 034 A1

(12)

(43) Date of publication:
09.07.2025 Bulletin 2025/28

(21) Application number: 23783204.3

(22) Date of filing: 01.09.2023
(51) International Patent Classification (IPC): 
C07D 487/10(2006.01)
A61K 31/499(2006.01)
 A61P 9/04(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 487/10; A61P 9/04
(86) International application number:
PCT/US2023/073355
(87) International publication number:
WO 2024/050539 (07.03.2024 Gazette 2024/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 02.09.2022 WO PCT/CN2022/116765

(71) Applicant: Cytokinetics, Inc.
South San Francisco CA 94080 (US)

(72) Inventors:
  • CHUANG, Chihyuan
    San Francisco, CA 94080 (US)
  • WANG, Xiaolin
    Beijing 100176 (CN)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) CRYSTALLINE FORMS OF 5-(3,4-DIFLUOROBENZYL)-8-((1R,4R)-4-METHYLCYCLOHEXYL)-6,9-DIOXO-2,5,8-TRIAZASPIRO[3.5]NONANE-2-CARBALDEHYDE